首页> 外文期刊>Scientific reports. >Methods for Scarless, Selection-Free Generation of Human Cells and Allele-Specific Functional Analysis of Disease-Associated SNPs and Variants of Uncertain Significance
【24h】

Methods for Scarless, Selection-Free Generation of Human Cells and Allele-Specific Functional Analysis of Disease-Associated SNPs and Variants of Uncertain Significance

机译:人类细胞无疤痕,无选择生成的方法以及与疾病相关的SNP和不确定性变异的等位基因特异性功能分析

获取原文
       

摘要

With the continued emergence of risk loci from Genome-Wide Association studies and variants of uncertain significance identified from patient sequencing, better methods are required to translate these human genetic findings into improvements in public health. Here we combine CRISPR/Cas9 gene editing with an innovative high-throughput genotyping pipeline utilizing KASP (Kompetitive Allele-Specific PCR) genotyping technology to create scarless isogenic cell models of cancer variants in ~1 month. We successfully modeled two novel variants previously identified by our lab in the PALB2 gene in HEK239 cells, resulting in isogenic cells representing all three genotypes for both variants. We also modeled a known functional risk SNP of colorectal cancer, rs6983267, in HCT-116 cells. Cells with extremely low levels of gene editing could still be identified and isolated using this approach. We also introduce a novel molecular assay, ChIPnQASO (Chromatin Immunoprecipitation and Quantitative Allele-Specific Occupation), which uses the same technology to reveal allele-specific function of these variants at the DNA-protein interaction level. We demonstrated preferential binding of the transcription factor TCF7L2 to the rs6983267 risk allele over the non-risk. Our pipeline provides a platform for functional variant discovery and validation that is accessible and broadly applicable for the progression of efforts towards precision medicine.
机译:随着全基因组协会研究的风险基因位点的不断出现以及从患者测序中发现不确定性的变异体,需要更好的方法将这些人类遗传学发现转化为公共健康的改善。在这里,我们将CRISPR / Cas9基因编辑与利用KASP(竞争性等位基因特异性PCR)基因分型技术的创新型高通量基因分型流程相结合,在约1个月内创建无变异的癌症变体等细胞模型。我们成功地模拟了我们实验室先前在HEK239细胞中PALB2基因中鉴定出的两个新变异体,从而产生了代表这两个变异体所有三种基因型的同基因细胞。我们还在HCT-116细胞中模拟了已知的结直肠癌功能风险SNP rs6983267。仍然可以使用这种方法鉴定和分离基因编辑水平极低的细胞。我们还介绍了一种新的分子测定法ChIPnQASO(染色质免疫沉淀和定量等位基因特异性职业),该技术使用相同的技术在DNA-蛋白质相互作用水平上揭示了这些变异体的等位基因特异性功能。我们证明了转录因子TCF7L2与rs6983267风险等位基因的优先结合超过了非风险。我们的产品线为功能变体发现和验证提供了一个平台,该平台可访问并且广泛适用于朝着精密医学方向发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号